Aquestive Therapeutics (AQST) Loans - Loss Allowance (2017 - 2021)

Aquestive Therapeutics' Loans - Loss Allowance history runs 5 years deep, the most recent figure standing at $40000.0 for Q1 2021.

• On a quarterly basis, Loans - Loss Allowance fell 52.38% year-over-year to $40000.0 in Q1 2021; TTM through Mar 2021 was $40000.0, a 52.38% decrease from a year earlier, with the FY2020 full-year figure at $40000.0, down 67.74% from the prior year.
• Loans - Loss Allowance was little changed at $40000.0 in Q1 2021 per AQST's latest filing, from $40000.0 in the prior quarter.
• Across five years, Loans - Loss Allowance topped out at $264000.0 in Q3 2020 and bottomed at $40000.0 in Q4 2020.
• The 5-year median for Loans - Loss Allowance is $64000.0 (2019), against an average of $88636.4.
• Biggest YoY gain for Loans - Loss Allowance was 180.85% in 2020; the steepest drop was 67.74% in 2020.
• Year by year, Loans - Loss Allowance stood at $55000.0 in 2017, then climbed by 5.45% to $58000.0 in 2018, then soared by 113.79% to $124000.0 in 2019, then slumped by 67.74% to $40000.0 in 2020, then changed by 0.0% to $40000.0 in 2021.
• Per Business Quant, the three latest AQST Loans - Loss Allowance figures stand at $40000.0 (Q1 2021), $40000.0 (Q4 2020), and $264000.0 (Q3 2020).